Filing Details
- Accession Number:
- 0001209191-24-000365
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-01-03 16:19:50
- Reporting Period:
- 2023-12-31
- Accepted Time:
- 2024-01-03 16:19:50
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1787297 | Passage Bio Inc. | PASG | Biological Products, (No Disgnostic Substances) (2836) | 822729751 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1799783 | B. Edgar Cale | One Commerce Square 2005 Market Street, 39Th Floor Philadelphia PA 19103 | Gc & Corporate Secretary | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-12-31 | 50,000 | $0.00 | 61,808 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-01-02 | 15,813 | $0.91 | 45,995 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Restricted Stock Unit | Disposition | 2023-12-31 | 50,000 | $0.00 | 50,000 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | M | Direct |
Footnotes
- Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
- Includes 1,024 shares acquired on May 14, 2021, 531 shares acquired on November 15, 2021, 3,082 shares acquired on May 13, 2022, and 3,967 shares acquired under the 2020 Employee Stock Purchase Plan.
- The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a "sell to cover" transaction.
- Each RSU represents a contingent right to receive one share of Issuer's common stock.
- 100% of the total restricted stock units vested on December 31, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Billionaire Hedge Funds
